Aspirin and statin use and the risk of gallbladder cancer

Kritika Prasai, Sri Harsha Tella, Siddhartha Yadav, Anuhya Kommalapati, Kristin Mara, Mohamed Mady, Mohamed A. Hassan, Nicha Wongjarupong, Natalia Rodriguez‐payan, Mitesh Borad, Tushar Patel, Lewis R. Roberts, Amit Mahipal

Research output: Contribution to journalArticlepeer-review


Aspirin and statin drugs have been associated with reduced risk of several gastrointestinal cancers, but their association with gallbladder cancer (GBC) has not been well established. We evaluated the association of aspirin and statins with the risk of GBC. Patients with GBC managed at Mayo Clinic between 2000 and 2019 were matched 1:2 with a general patient pool by age and sex. Univariable and multivariable logistic regression models were used to assess associations between GBC and aspirin or statin use. The analysis included 795 cases and 1590 controls, with a median age of 67 years. Aspirin or statin use alone or in combination was higher in controls (p < 0.001). Univariate analysis showed that the use of aspirin [odds ratio (OR):0.11; 95%CI: 0.08–0.15] or statins (OR: 0.29; 95%CI: 0.20–0.40) and their combined use (OR: 0.18; 95%CI: 0.13–0.24) was associated with lower risk of GBC. Multivariable analysis revealed that aspirin (OR: 0.12; 95%CI: 0.09–0.16) and combined statins and aspirin (OR: 0.46; 95%CI: 0.31–0.67) were associated with lower risk of GBC. Aspirin alone or in combination with statins is associated with a strongly reduced risk of GBC. Further prospective studies are needed to confirm these results and to elucidate their mechanisms.

Original languageEnglish (US)
Article number1186
Pages (from-to)1-10
Number of pages10
Issue number5
StatePublished - Mar 1 2021


  • Aspirin
  • Cancer prevention
  • Gallbladder cancer
  • Statin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Aspirin and statin use and the risk of gallbladder cancer'. Together they form a unique fingerprint.

Cite this